Join
Live feed
·
PRReleasevia Quantisnow
Tenaya Therapeutics Inc. logo

Tenaya Therapeutics Presents Promising Interim Clinical Data from MYPEAK™-1 Phase 1b/2a Clinical Trial of TN-201 Gene Therapy for the Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy

ByQuantisnow·Wall Street's wire, on your screen.
TNYA· Tenaya Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track TNYA (Tenaya Therapeutics Inc.) and more on Quantisnow.